InflaRx prices $40M offering
- Clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,InflaRx N.V. (NASDAQ:IFRX) priced its underwritten public offering of ~9.42M shares at an offering price of $4.25 per share.
- The offering is expected to close on April 14, 2023.
- Underwriters' have 30-day option to purchase up to ~1.41M additional shares.
- Net proceeds to fund the continued development of vilobelimab, general research and development expenses and investments in the company’s commercial infrastructure and for working capital and general corporate purposes.
- Stock price marginally up 0.40%.